Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Raw Materials: 2014-2024

Historic Raw Materials for Ocular Therapeutix (OCUL) over the last 11 years, with Dec 2024 value amounting to $214,000.

  • Ocular Therapeutix's Raw Materials rose 16.84% to $229,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $229,000, marking a year-over-year increase of 16.84%. This contributed to the annual value of $214,000 for FY2024, which is 29.14% down from last year.
  • Ocular Therapeutix's Raw Materials amounted to $214,000 in FY2024, which was down 29.14% from $302,000 recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Raw Materials registered a high of $388,000 during FY2021, and its lowest value of $214,000 during FY2024.
  • For the 3-year period, Ocular Therapeutix's Raw Materials averaged around $275,000, with its median value being $302,000 (2023).
  • As far as peak fluctuations go, Ocular Therapeutix's Raw Materials soared by 76.96% in 2020, and later fell by 29.14% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Raw Materials (Yearly) stood at $384,000 in 2020, then climbed by 1.04% to $388,000 in 2021, then decreased by 20.36% to $309,000 in 2022, then decreased by 2.27% to $302,000 in 2023, then declined by 29.14% to $214,000 in 2024.